Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)

Authors not listed

University of Birmingham · 2016

Abstract

This study is designed to assess the physiological consequences of elevating Nicotinamide Adenine Dinucleotide (NAD+) availability using Nicotinamide Riboside (NR) supplementation in skeletal muscle tissue, and examine its effect upon muscle metabolic phenotype.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-10-27 MST

Cite this

APA
Anonymous. (2016). Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet). <em>University of Birmingham</em>. https://clinicaltrials.gov/study/NCT02950441
Vancouver
Anonymous. Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet). University of Birmingham. 2016.
BibTeX
@misc{anon2016Nicoti, title = {Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)}, author = {Anonymous}, journal = {University of Birmingham}, year = {2016}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings